8-KRegulation FD

QUEST DIAGNOSTICS INC 8-K Report, Regulation FD Disclosure (Mar 20, 2009)

Filed March 20, 2009For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on March 20, 2009, to disclose a significant share repurchase transaction. On March 19, 2009, the company bought back 4,511,657 shares of its common stock from SB Holdings Capital Inc., a subsidiary of GlaxoSmithKline plc. This transaction was executed under the company's existing share repurchase authority. The aggregate purchase price for these shares was $200,000,013.31. The filing notes that the purchase price represented a negotiated discount compared to the volume-weighted average trading price of DGX's common stock in the period leading up to the repurchase. This event signals a strategic use of capital by Quest Diagnostics to reduce outstanding shares, potentially aiming to enhance shareholder value through a lower share count.

Key Highlights

  • 1Quest Diagnostics repurchased 4,511,657 shares of its common stock on March 19, 2009.
  • 2The seller of the shares was SB Holdings Capital Inc., a subsidiary of GlaxoSmithKline plc.
  • 3The total cost of the share repurchase was $200,000,013.31.
  • 4The transaction was conducted under the company's existing share repurchase program.
  • 5The purchase price reflected a negotiated discount to the market price.
  • 6This action indicates a capital allocation strategy focused on reducing share count.

Frequently Asked Questions

Quest Diagnostics repurchased shares as part of its existing share repurchase authority, likely to reduce the number of outstanding shares and potentially enhance shareholder value.

The shares were repurchased from SB Holdings Capital Inc., which is a wholly-owned subsidiary of GlaxoSmithKline plc.

This appears to be a private transaction, as the shares were purchased from a specific entity (SB Holdings Capital Inc.) and the price was 'negotiated', reflecting a discount to the volume-weighted average trading price.

The negotiated discount suggests Quest Diagnostics was able to acquire shares at a favorable price, potentially offering a better value than open market purchases at that time. This indicates an opportunistic capital deployment strategy.